OliX Pharmaceuticals Announces Completion of Enrollment in Phase 2 Clinical Trial of OLX101A in Patients with Hypertrophic Scars
SUWON, South Korea--(BUSINESS WIRE)--#ClinicalTrial--OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced the completion of patient...







